Air Street Capital is a VC firm investing in AI-first technology and life science companies. The firm recently announced that it closed a new $121 million fund.
In a blog post, Air Street Capital founder and general partner Nathan Benaich said:
“We are delighted to announce Air Street Capital’s second fund of $121,212,121. As a firm, we now have significant resources and long-term capital partners to match the ambitions of our founders.
AI is a force multiplier for technology, helping us to unlock a new era of economic progress and scientific discovery. Excitement has exploded around AI since last summer, with companies of all sizes, media, politicians, and investors coming into the fold en masse. There is still so much more to discover and build with the field being in its early real-world deployment phase.”
Air Street believes that AI founders deserve an AI-native investor. In the first fund, the firm invested in 19 AI-first technology and life science companies across North America and Europe. These are some of the highlights from that fund:
– Allcyte (functional drug screening) was acquired by Exscientia, which subsequently went public on the Nasdaq as the most prominent European biotech IPO of all time and becoming the third largest biopharma company in the UK after AstraZeneca and GSK,
– Nasdaq-listed Recursion Pharmaceuticals acquired Valence Discovery (generative chemistry) to create Valence Labs, an “OpenAI/DeepMind” for drug discovery,
– Intenseye (health and safety) and V7 (AI data platform) are accelerating into the growth stage as they service large global enterprises.
